WT1 Peptide Immunotherapy Prediction via IgG Subclass Titers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the clinical effect of WT1 peptide immunotherapy lack accuracy, making it difficult to determine the appropriateness of continued administration and assessing long-term treatment outcomes in patients with WT1-associated diseases.
Innovation Solution
A method involving the measurement of IgG antibody titers against WT1 antigen peptides, specifically using WT1 antigen peptides corresponding to the WT1 peptide vaccine, to assess the clinical effect by detecting binding and determining the subclasses IgG1, IgG3, and IgG4 levels, which correlates with overall survival and progression-free survival rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to predict clinical effect, then the prediction process is simple, but the accuracy of prediction is low
Solution Approach 1:
The patent segments the IgG antibody measurement into four distinct subclasses (IgG1, IgG2, IgG3, IgG4) and measures each separately. This segmentation allows for more precise prediction of clinical effect by capturing the nuanced immune response profile, where different subclasses contribute differently to therapeutic efficacy. The segmented measurement approach resolves the contradiction by sacrificing some system complexity to gain significant improvement in prediction accuracy.
Solution Approach 2:
The patent changes the measurement parameter from total IgG antibody level to specific IgG subclass titers (IgG1, IgG2, IgG3, IgG4). This parameter change enables more accurate prediction of clinical effect by detecting subtle variations in immune response that total IgG measurement cannot capture. The principle resolves the contradiction by transforming a simple measurement into a multi-parameter analysis that provides superior predictive accuracy.
2Measurement precision
If IgG antibody titer measurement is performed to predict clinical effect, then prediction accuracy improves, but the measurement time and complexity increase
Solution Approach 1:
The patent performs preliminary classification of the immune response by measuring all four IgG subclasses at predetermined time points (e.g., 4 weeks, 8 weeks, 12 weeks post-vaccination). This preliminary action establishes a baseline immune profile that correlates with long-term clinical outcomes. By conducting the comprehensive measurement early in the treatment protocol, the patent avoids the need for prolonged monitoring, thus resolving the contradiction between measurement time and prediction accuracy.
Solution Approach 2:
The patent establishes a feedback mechanism where the measured IgG subclass titers are correlated with clinical outcomes (overall survival rate, progression-free survival rate). This feedback loop validates the measurement approach and allows for optimized prediction without requiring continuous long-term monitoring. The feedback principle resolves the time-accuracy contradiction by demonstrating that a single comprehensive measurement can predict long-term outcomes.
3Measurement precision
If multiple IgG subclasses are measured separately, then prediction accuracy increases, but the ease of operation decreases
Solution Approach 1:
The patent employs a universal measurement platform that can simultaneously or sequentially measure all four IgG subclasses using standardized ELISA protocols. This multi-functional approach maintains operational simplicity while achieving precise measurement of each subclass. The universal platform resolves the contradiction by allowing the same basic methodology to be applied across different measurements, reducing the operational burden despite the increased measurement scope.
Solution Approach 2:
The patent uses identical ELISA measurement protocols for each IgG subclass, essentially creating copies of the same measurement process adapted for different antibody subclasses. This copying approach maintains ease of operation by repeating a proven, standardized procedure rather than developing complex new methods for each subclass. The principle resolves the contradiction by leveraging the simplicity of a single well-established method applied multiple times.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate prediction of clinical effects, allowing for better judgment on the continuation of WT1 peptide vaccine administration and improving treatment outcomes by measuring anti-WT1 antigen peptide IgG antibody titers at specific time points post-administration.
Implementation Method 1
contacting a sample from the subject who has been given a WT1 peptide vaccine with a WT1 antigen peptide... and detecting the binding of the sample to the WT1 antigen peptide
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a method for predicting a clinical effect on a subject in a WT1 peptide immunotherapy, said method comprising: a) a step for contacting a sample derived from the subject with WT1 antigen peptide or a variant thereof; and b) a step for detecting the binding of the sample to the WT1 antigen peptide or a variant thereof and thus measuring anti-WT1 antigen peptide IgG antibody titer existing in the sample, characterized in that an increase in the anti-WT1 antigen peptide IgG antibody titer in the subject determines the achievement of a favorable clinical effect. Also provided is a kit for performing the method according to the present invention, said kit containing WT1 antigen peptide or a variant thereof.